Histogen Inc. is a clinical-stage therapeutics company focused on developing potential first-in class clinical and preclinical small molecule pan-caspase and caspase selective inhibitors that protect the body’s natural process to restore immune function. Our pipeline includes emricasan, CTS-2090 and other proprietary caspase inhibitors. We believe that emricasan has the potential to treat infections in a different way; by protecting the competence of the body’s immune system thereby restoring the body’s natural process to combat invading organisms. By focusing on optimizing the immune response, we believe that emricasan can be a viable option for physicians to treat and cure certain infectious diseases without the risk of generating resistance. CTS-2090 and other proprietary selective small molecule inhibitors of caspase-1 are designed for the treatment of certain inflammatory diseases. For more information, please visit www.histogen.com.
Company profile
Ticker
HSTO
Exchange
Website
CEO
Steven Mento
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Conatus Pharmaceuticals Inc, Conatus Pharmaceuticals Inc.
SEC CIK
Corporate docs
Subsidiaries
1.Histogen Therapeutics, Inc. • 2.Centro de Investigación de Medicina Regenerativa, S.A. de C.V. ...
IRS number
203183915
HSTO stock data
Latest filings (excl ownership)
15-12G
Securities registration termination
4 Jan 24
DEFA14A
Additional proxy soliciting materials
15 Dec 23
425
Business combination disclosure
14 Dec 23
8-K
Histogen Announces Second Adjournment of Special Meeting of Stockholders
14 Dec 23
425
Business combination disclosure
5 Dec 23
8-K
Histogen Announces Adjournment of Special Meeting of Stockholders
5 Dec 23
S-8 POS
Registration of securities for employees (post-effective amendment)
16 Nov 23
S-8 POS
Registration of securities for employees (post-effective amendment)
16 Nov 23
S-8 POS
Registration of securities for employees (post-effective amendment)
16 Nov 23
S-8 POS
Registration of securities for employees (post-effective amendment)
16 Nov 23
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 4.87 mm | 4.87 mm | 4.87 mm | 4.87 mm | 4.87 mm | 4.87 mm |
Cash burn (monthly) | 895.33 k | 839.92 k | 1.18 mm | 1.00 mm | 896.33 k | 839.50 k |
Cash used (since last report) | 5.34 mm | 5.01 mm | 7.00 mm | 5.99 mm | 5.34 mm | 5.00 mm |
Cash remaining | -463.92 k | -133.59 k | -2.13 mm | -1.12 mm | -469.88 k | -131.11 k |
Runway (months of cash) | -0.5 | -0.2 | -1.8 | -1.1 | -0.5 | -0.2 |
Institutional ownership, Q2 2023
9.2% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 14 |
Opened positions | 2 |
Closed positions | 2 |
Increased positions | 2 |
Reduced positions | 3 |
13F shares | Current |
---|---|
Total value | 107.80 mm |
Total shares | 391.96 k |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Intracoastal Capital | 240.38 k | $0.00 |
Vanguard | 60.17 k | $42.78 mm |
BLK Blackrock | 34.91 k | $24.83 mm |
MS Morgan Stanley | 16.10 k | $11.45 mm |
Two Sigma Securities | 10.49 k | $7.46 mm |
Geode Capital Management | 10.25 k | $7.30 mm |
SNV Synovus Financial | 10.05 k | $7.15 mm |
Tower Research Capital | 9.27 k | $6.59 mm |
Advisor | 275.00 | $196.00 k |
WFC Wells Fargo & Co. | 31.00 | $22.00 k |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
20 Jun 23 | Rochelle Fuhrmann | Stock Option Common Stock | Grant | Acquire A | No | No | 0.828 | 6,835 | 5.66 k | 6,835 |
20 Jun 23 | David Hugh Crean | Stock Option Common Stock | Grant | Acquire A | No | No | 0.828 | 6,835 | 5.66 k | 6,835 |
20 Jun 23 | Brian Satz | Stock Option Common Stock | Grant | Acquire A | No | No | 0.828 | 6,835 | 5.66 k | 6,835 |
20 Jun 23 | Susan Richards Windham-Bannister | Stock Option Common Stock | Grant | Acquire A | No | No | 0.828 | 6,835 | 5.66 k | 6,835 |
20 Jun 23 | Kisner Daniel L | Stock Option Common Stock | Grant | Acquire A | No | No | 0.828 | 6,835 | 5.66 k | 6,835 |